Tscan therapeutics announces transition of chief financial officer

Waltham, mass., june 29, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-ts) for the treatment of patients with cancer, today announced that its chief financial officer, brian m. silver, j.d., will be leaving the company, effective july 21, 2023, to pursue a new opportunity at a leading advisory firm based in new york, where he lives with his family. brian will continue to be available to provide strategic advice for the company. the company has initiated a search for a successor chief financial officer.
TCRX Ratings Summary
TCRX Quant Ranking